Autoimmune diseases are on the rise, and for many of your patients, they’re life-defining. Two of the most commonly used supplements in integrative practice — vitamin D and marine omega-3 fatty acids — may play a particularly important role in autoimmune disease prevention in adults over 50.
Large-scale clinical data (the VITAL study), published in The BMJ, offers some of the strongest evidence to date that vitamin D, and possibly marine omega-3s, can help halt autoimmune disease in older adults.
Who Was Studied and What They Took
The VITAL trial enrolled 25,871 community-dwelling adults across the U.S. Men were 50 and older; women were 55 and older. The average age was 67, and the cohort was racially diverse: about 71% non-Hispanic white, 20% Black, and 9% other racial or ethnic groups (see Table 1 in PDF). Participants were generally typical of an older U.S. outpatient population — not selected for autoimmune risk.
The design was a classic 2×2 factorial:
- Vitamin D3: 2,000 IU per day vs placebo
- Marine omega-3s: 1,000 mg per day of fish oil (460 mg EPA + 380 mg DHA) vs placebo
That created four groups: vitamin D alone, omega-3 alone, both, or neither (double placebo). Supplements were taken for about 5.3 years, with high adherence and excellent follow-up. Each year, participants reported new doctor-diagnosed autoimmune conditions. The primary outcome included:
- Rheumatoid arthritis
- Polymyalgia rheumatica/giant cell arteritis
- Autoimmune thyroid disease
- Psoriasis
- Inflammatory bowel disease and other autoimmune diagnoses
Crucially, these weren’t just self-reported labels. Two physicians, blinded to treatment assignment, reviewed medical records and confirmed (or rejected) each case. Some cases were classified as “probable” when documentation was incomplete, especially for autoimmune thyroid disease.
What Did Vitamin D and Omega-3s Actually Do?
The cumulative incidence curves tell an important story: over time, the lines for the supplement groups drift away from the placebo lines, especially for vitamin D.
Vitamin D3 (2,000 IU/day):
- 123 people on vitamin D vs 155 on vitamin D placebo developed a confirmed autoimmune disease.
- That’s a hazard ratio of 0.78 (95% CI 0.61–0.99; P=0.05) — about a 22% relative risk reduction.
Because autoimmune diseases develop slowly, the investigators also repeated the analysis excluding the first two years of follow-up. When they did that, the effect got stronger:
- Hazard ratio for confirmed autoimmune disease after year 2: 0.61 (0.43–0.86; P=0.005)
- Roughly a 39% reduction in risk with longer-term vitamin D use.
Marine omega-3s (1 g/day EPA/DHA):
- 130 people on omega-3 vs 148 on placebo developed a confirmed autoimmune disease.
- Hazard ratio 0.85 (0.67–1.08; P=0.19) — a favorable trend, but not statistically significant.
- When probable and confirmed cases were combined: Hazard ratio improved to 0.82 (0.68–0.99; P=0.04) — about an 18% reduction in total autoimmune events.
Combination vs double placebo:
The 2×2 comparison is particularly practical — compared to vitamin D placebo + omega-3 placebo:
- Vitamin D + omega-3: HR 0.69 (0.49–0.96)
- Vitamin D alone: HR 0.68 (0.48–0.94)
- Omega-3 alone: HR 0.74 (0.54–1.03), borderline but trending beneficial
There was no significant interaction between vitamin D and omega-3s, suggesting vitamin D is the main driver, with omega-3s offering a modest additional benefit.
Who Seemed to Benefit the Most?
The subgroup data offer some helpful clinical nuance:
- Lower BMI:
The preventive effect of vitamin D was strongest in leaner participants. For vitamin D vs placebo:- BMI <25: HR 0.62 (0.42–0.93)
- BMI 25–30: HR 0.92 (0.61–1.38)
- BMI ≥30: HR 0.88 (0.54–1.44)
- Family history of autoimmunity:
For omega-3s, the benefit was more apparent in participants with a family history of autoimmune disease:- With family history: HR 0.66 (0.43–0.99)
- Without family history: HR 1.14 (0.82–1.58); P for interaction=0.03
- Other factors — age, sex, race, baseline vitamin D or omega-3 status — did not show clear, consistent interaction effects.
Why Might These Nutrients Help?
The Discussion section (pages 11–12 of PDF) walks through mechanisms that are very much in line with what integrative clinicians already teach.
For vitamin D, the active form (1,25-dihydroxyvitamin D):
- Binds vitamin D receptors on dendritic cells, T and B lymphocytes, and macrophages.
- Downregulates Th1 and Th17 patterns, including IL‑2, IL‑12, IFN‑γ, TNF, and IL‑6.
- Reduces B-cell autoantibody production.
- Promotes regulatory T cells and a more tolerogenic immune environment.
For omega-3 fatty acids (EPA/DHA):
- Modulate cytokines such as TNF-α, IL‑1β, IL‑6, and CRP in many (though not all) studies.
- Influence T-cell activation and proliferation.
- Serve as substrates for pro-resolving mediators like resolvins, protectins, and maresins that actively resolve inflammation rather than simply suppress it.
Interestingly, a VITAL substudy did not show big changes in standard systemic inflammatory markers after one year of supplementation, suggesting autoimmune prevention may depend on longer-term or more subtle immune shifts rather than short-term CRP changes.
The clinical importance of these findings is high because these are well tolerated, non-toxic supplements, and other effective treatments to reduce the incidence of autoimmune diseases are lacking. Additionally, we saw consistent results across autoimmune diseases and increasing effects with time.
How Does This Inform Your Practice?
For naturopathic and integrative clinicians, these findings are highly actionable:
- The doses are clinically familiar: vitamin D3 at 2000 IU/day and fish oil at 1 g/day (≈460 mg EPA, 380 mg DHA).
- The time frame matters: meaningful risk reduction appeared after years, not months, of consistent use.
- The effect is preventive, not curative: this is about lowering the risk of developing autoimmune disease, not treating flares.
Patients who may be especially appropriate candidates for this conversation include:
- Older adults (50s, 60s, 70s) with a family history of autoimmune disease
- Individuals with normal-to-lower BMI, where vitamin D’s effect appears stronger at this dose
- Patients already taking vitamin D or fish oil for bone, mood, or cardiometabolic reasons, where autoimmune prevention is an added potential benefit
Study Limitations
These results may not generalize to younger people or to conditions that usually start earlier in life (e.g., type 1 diabetes). Only one dose of each supplement was tested. The study was powered for a composite outcome, not individual diagnoses, so we should be cautious about disease-specific claims. And we don’t yet know how long the benefit persists beyond five years, although an extension study is underway.
Even with those caveats, the autoimmune findings from VITAL are a milestone. They provide large, randomized, placebo-controlled evidence that daily vitamin D3 at 2,000 IU, and to a lesser extent, marine omega-3s, can reduce the incidence of autoimmune disease in older adults. For a field that has long emphasized terrain, immune tolerance, and early prevention, this trial offers rare, high-level support for a strategy many of you are already implementing: thoughtful, long-term use of vitamin D and fish oil as part of a broader autoimmune prevention plan.
→ Download the Full Text HERE.
Reference
Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, Kotler G, Lee IM, Manson JE, Costenbader KH. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022 Jan 26;376:e066452. doi: 10.1136/bmj-2021-066452. PMID: 35082139; PMCID: PMC8791065.
